U.S. Food and Drug Administration (FDA) Commissioner Martin Makary announced a new policy directive limiting employees of companies the agency regulates, such as pharmaceutical companies, from serving as official members of FDA advisory committees. “While the FDA should be partnering with industry to ensure a user-friendly review process, the scientific evaluation of new products should be independent,” Makary said. “Industry employees are welcome to attend FDA advisory committee meetings, along with the rest of the American public, but having industry employees serve as official members of FDA advisory committee members represents a cozy relationship that is concerning to many Americans,”...